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Abstract. Five out of six human melanoma cell lines
tested were able to degrade in vitro a smooth muscle
cell extracellular matrix in a plasmin-dependent way.
In three of these five cell lines, this process was medi-
ated by tissue-type plasminogen activator (t-PA) and in
the other two cell lines by urokinase-type plasminogen
activator (u-PA).
All melanoma cell lines produced t-PA mRNA and
protein, whereas only the two cell lines showing u-PA-
mediated matrix degradation produced u-PA mRNA
and protein . These latter cell lines also produced plas-
minogen activator inhibitor type-1 (PAI-1) and type-2
(PAI-2) mRNA and protein . u-PA receptor (u-PA-R)
mRNA and binding of radiolabeled u-PA was found in
all melanoma cell lines. The metastatic capacity of
these cell lines was studied in nude mice. All cell
lines were able to develop primary tumors at the sub-
RING metastasis, tumor cells must penetrate base-
ment membranes and interstitial tissues, when they
detach from the primary tumor and intravasate into
the circulation, and later when they extravasate at the site
formation of the secondary tumor. This means that these tu-
mor cells should express the right panel and adequate levels
of proteolytic enzymes to degrade the extracellular matrix
(15, 16, 24, 34, 49, 57) . In addition, these enzymes may have
a function in the process of angiogenesis when endothelial
cells grow invasively into the newly formed tumor and form
new blood vessels (25, 38) . The serine protease plasmin is
one ofthe majorenzymes believed to be involved in such pro-
teolytic processes (15, 16, 24, 42, 43). Plasmin has a broad
substrate specificity and can digest most of the components
of the extracellular matrix including the basement mem-
brane, either directly or by activation of proenzymes of
metalloproteinases, like type IV collagenase or interstitial
collagenase (23, 39, 57) . Plasmin is formed by a conversion
of the zymogen plasminogen, which is regulated by plas-
minogen activators. Two distinct plasminogen activators
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cutaneous inoculation site. The production of plasmino-
gen activators, their inhibitors and urokinase receptor
by subcutaneous tumors corresponded with the pro-
duction by the parental cell lines in vitro.
The two u-PA and PAM producing cell lines showed
the highest frequency to form spontaneous lung meta-
stases after subcutaneous inoculation, whereas five of
the six cell lines formed lung colonies after intrave-
nous inoculation .
In conclusion, u-PA mediated matrix degradation in
vitro and production of u-PA and PAI-1 by human
melanoma cell lines correlated with their ability to
form spontaneous lung metastasis in nude mice. No
correlation was found with the ability to form lung
colonies after intravenous injection. These findings
suggest a role for u-PA and PAI-1 in a relatively early
stage of melanoma metastasis.
are known, the tissue-type (t-PA),' and the urokinase-type
(u-PA). The activity ofthe activators can be regulated by in-
teractions with specific inhibitors, of which two have been
described, type 1(PAI-1) and type 2 (PAI-2) (33, 53). In addi-
tion, u-PA and its proenzyme, pro-u-PA, can be localized at
cell surfaces by binding through their growth factor domain
to a specific receptor (u-PAR) (2, 8, 12, 41, 51, 55, 56, 62).
To study the role of plasminogen activation system in
metastasis ofmalignant melanomas, we have investigated the
occurrence of its various components and their mRNA in a
set of six human melanoma cell lines with different meta-
static behavior in the nude mice. To study the different steps
in the metastatic process (primary tumor growth, local inva-
sion and detachment oftumor cells from the primary tumor,
lodgementand invasion indistant tissues) the cells were inoc-
ulated either subcutaneously or intravenously.
1. Abbreviations used in this paper: PAI, plasminogen activator inhibitor;
t-PA, tissue plasminogen activator; u-PA, urokinase plasminogen activator;
u-PAR, urokinase plasminogen activator receptor.Furthermore, the ability of tumor cells to degrade ex-
tracellular matrix produced by smooth muscle cells was used
as an in vitro model in which the effects of anticatalytic anti-
bodies against t-PA and u-PA were tested .
Materials andMethods
CellLines
All cell lines were derived from humanmelanoma metastases . The IF6 (59)
andMV3 (60) cell lines weredeveloped fromlymphnodemetastasesoftwo
different malepatients. The BLM cell line is a subline ofBRO (35) and was
isolated from lung metastases after subcutaneous inoculation of nude mice
withBRO cells . The M14 (31) cell line was obtained from Dr. A. Cochran
(John Wayne Clinic, Johnsson Comprehensive Cancer Center, UCLA
School ofMedicine, Los Angeles, CA) . The Me157 (9) cell line was kindly
provided by Dr. J. de Vries (The Netherlands Cancer Institute, Amsterdam,
The Netherlands) . The 530 cell line (64) was established and kindly
provided by Dr. E 1 . Schrier (University Hospital, Leiden, The Nether-
lands) .
Cell Culture
All cell lines were grown as monolayers in DME medium supplemented
with 10% FCS, 2mM glutamine, 100 U/ml penicillin, and 100 pg/ml strep-
tomycin . To determine the protein andmRNA levels ofplasminogen activa-
tors and their inhibitors fresh serum containing medium was added to the
cell cultures shortly before they reached confluency, 24 h later when the
cells had reached confluency, the conditioned medium was collected and
cell extracts were prepared for antigen determination and RNA isolation .
AssayforPA andPAIAntigen
Antigenlevels oft-PA, u-PA, PAW, and PAI-2 were determined in both con-
ditioned media and cell extracts (extracted with 0.5% Triton X-100 and
scraped with a rubber policeman) of cultured human melanoma cell lines.
The antigen levels in tissue extracts of subcutaneous tumors derived from
these cell lines after inoculation in nude mice were also determined . Ex-
tracts of subcutaneous tumors in nude mice were prepared using 0.1M Tris.
HCl (pH 7.5)/0.1% Tween 80 as a homogenization buffer. The final extracts
contained 50 mg tumor tissue/nil .
t-PA antigen was determined using the commercial ELISA Imulyse t-PA
(Biopool, Umed, Sweden) . u-PA antigen was determined with a sandwich
ELISA, described in detail by Binnema et al . (6) . As a standard, either
purified t-PA or u-PA was used, which was standardized against the respec-
tive International Standard preparations on an activity basis using the
specific activities of 500,000 IU/mg t-PA (22) and 100,000 IU/mg u-PA
(WHO preparation c66/46) (48) . PAM and PAI-2 antigen were determined
using the commercial ELISAs Tmtelize Stripwell PAI-1 and Tintelize PAI-2
(Biopool) . Detection limits for these assays are x+10 ng for t-PA and u-PA,
5 ng for PAI-1 and 2 ng for PAI-2 per ml .
All determinations were performed in duplicate . Serum containing non-
conditioned medium was used as control .
mRNA Analysis
Cells were washed with PBS at 37°C and lysed in 4M guanidium thiocya-
nate, 25 mM sodium citrate, pH 7.5, 0.5% sarkosyl, 0.1 M 2-mercapto-
ethanol . RNA was isolated according to Chomczynski and Sacchi (11) . The
total amount ofRNA isolated was determined by measuring the OD26o, as-
suming that 1 OD260 unit is equivalent to 40 jug RNA.
RNA samples were electrophoresed on a 1.2% denaturating agarose gel
containing 7.5% formaldehyde and were transferred to a nylon membrane
(HybondN ; Amersham International, Amersham, United Kingdom) using
a Vacugene system (Pharmacia, Uppsala, Sweden) . Membranes were hy-
bridized with 32plabeled cDNA fragments in 7% SDS, 0.5 M NaHPO2,
pH 7.2, 10mM EDTA at 60°C . Blots were routinely washed with 2 x SSC,
1% SDS for 1 h at60°C (lx SSC = 0.15M NaCl, 0.015M sodium citrate) .
cDNA fragments were labeled using the random primer method (Mul-
tiprime ; Amersham International), with 32P-dCTP (specific activity was
"109 cpm/pg DNA) . Autoradiograms were prepared using Kodak XAR-5
films and intensifying screens at -70°C.
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mRNA Quantification
mRNA levels were determined as described by Quax et al . (48) using dot
blots containing series ofdilutionsofinvitrotranscriptsoft-PA, u-PA, PAI-1
and PAI-2 as standards. These RNA transcripts were made using T7 RNA
polymerase (Promega Biotec, Leiden, The Netherlands) . After removal of
the DNA templates with RQl DNAse (Promega Biotec), the amounts of
RNA transcripts synthesized were determined by measuring OD260 . As an
internal standard 0-actin was used .
cDNA Probes
For the hybridization experiments thefollowing cDNA fragments wereused
as probes : a 1.9-kb Bg1II fragment of the human t-PA cDNA (61), a 1.0-kb
EcoRI-PstI fragment ofthe human u-PAcDNA (37), a 1.2-kb Pstlfragment
of the human PAI-1 cDNA (58), a 1.2-kb EcoRI fragment of the human
PAI-2 cDNA, kindly provided by Dr. E. K . O . Kruithof(52), and a 1.2-kb
Pstl fragment of a hamster 13-actin cDNA, kindly provided by Dr. W. J .
Quax (18) .
As a probe for the u-PA receptormRNA the p-uPAR-1 plasmid contain-
ing the complete cDNA for human u-PAR (51) was used after random
primer labeling and hybridization performed as described earlier (36) .
ExtracellularMatrix PreparationandDegradation
Bovine smooth muscle cells (kindly provided by Dr. G . Sperti, Hammer-
smith Hospital, London) were grown to confluency inDME medium sup-
plemented with 10% FCS, 2mM glutamine, 100 U/ml penicillin, and 100
mg/ml streptomycin in 2-cm2 culture dishes . After the cultures had reached
confluency and the formation of extracellular matrix was started, the cells
were incubated for 4 d with medium containing a [ 3H]amino acid mixture
(1 140/ml, Amersham International) . Cells were thenlysed using 0.5% Tri-
tonX-100 in PBSand the cytoskeleton was removedby 25mM ammonium-
hydroxide treatment . Unincorporated [ 3H]amino acids were washed from
the remaining extracellular matrix using H2O (twice) and 75% ethanol .
Matrices were dried and stored at -20°C until use. Before tumorcells were
seeded onto the 3H-labeled matrices, the latter were soaked with medium
for 1 h . For the extracellular matrix degradation assay 10, cells/2-cm' dish
were seeded ontothe matrix in 10 % FCS containingDME mediumorDME
medium supplemented with 100 U/ml aprotinin (as plasmin inhibitor) or
specific inhibiting antibodies against t-PA (50) or u-PA (6) . Antibody con-
centrations used were -30pg/ml for anti-t-PAand 300 Eag/ml for anti-u-PA .
Human plasminogen, purified by affinity chromatography as described pre-
viously (63), was added to the medium in all experiments to a final concen-
tration of 0.14 AM . After 2 d, the conditioned medium was removed and
the remaining matrix was degraded with 0.25% trypsin (1 h at 37°C) .
[3H]Amino acid release was determined and the 3H release by the tumor
cells was expressed as percentage of the total amount of 3H released (the
sum of the release by the cells and by the trypsin treatment),
u-PA ReceptorAnalysis
The presence of u-PAR in the cells was determined essentially according
to Nielsen et al . (41) . Tumor cells were grown to confluency in DME
medium plus 10% FCS, detached from the culture dishes using a rubber
policeman and washed twice with PBS . After a moderate acid treatment
(0.05 M glycine, pH 3 .0, 0 .1 M NaCl ; for 3 min at room temperature) to
remove the endogenous u-PA from the receptor, cells were lysed in 0.1 M
Tris-HCl pH 8 .1, 1% Triton X-114, 10 mM EDTA, 100 U/ml aprotinin,
1 mM PMSF and centrifuged for 10 min at 10,000 g . The supernatant was
stored at -20°C. Diisopropylfluorophosphate (DFP)-treated u-PA (5)
(kindly provided by Dr. N. Behrendt, Finsen Laboratory, Copenhagen) was
radiolabeled using Na-1251 according the Iodogenprocedure (Pierce Chem-
ical Co., Rockford, IL) . u-PA receptorwasdetermined in crudecell extracts
by incubation of a sample of the cell extract (of "25,000 cells) with 125j
labeled DFP treated u-PA, with or without addition of a 100-fold excess of
unlabeled u-PA, in 20 Al PBS, 0.1% Tween 80 for 1 h at 4°C, followed by
incubation with the crosslinking agent disuccinimidyl suberate (2 mM) for
15 min at room temperature and with ammonium acetate (10 mM) for 10
min at room temperature . The samples were then analyzed by SDS-PAGE
and autoradiography using KodakXAR5 film and intensifying screens at
-70°C . Extracts of subcutaneous tumor tissue (50 mg/ml) were prepared
by homogenization in 0.2 M Tris-HCI (pH 7.5) . Subsequently, membrane
fractions were purifiedby centrifugation ofthe extracts in an airfuge (Beck-
man Instruments, Fullerton, CA) at 130,000 g for 15 min . The pellet was
resuspended in glycine buffer (0.05M glycine, pH 3 .0, 0.1 M NaCI), centri-
192fuged for 15 min at 130,000 g, resuspended in 0.1 M Tris-HCI pH 8.1, 1%
Triton X-114, 10mM EDTA, 100U/ml aprotinin, 1 mM PMSF,and finally
centrifuged for 10 min at 10,000 g . Analysis for presence of u-PAR in the
supernatant was performed as described above.
NudeMice
Balb/c athymic nude mice (nu/nu) were purchased from the Laboratory
Breeding Research Center (GI . Bomholtgaard, Ry, Denmark) and kept in
separate rooms in cages coveredwith air filters underSPF conditions . Mice
were used when 4-6 wk old and were sex matched.
7lumor Cell Inoculation
Melanoma cells were harvested from subconfluent cultures by trypsiniza-
tion, washed twice with serum containing medium, suspended in PBS (1-2
x 107 cells/ml) and inoculated (a) subcutaneously into the lateral thoracic
wall to produce tumors at the inoculation site and to produce pulmonary
metastases or (b) intravenously into thelateral tail veintoproduce lung col-
onies. 1-2 x 106Tumor cells were injected in both cases . Mice were rou-
tinely checked twiceaweekand killed when signs of illness were noted or,
when they remained healthy, 3-4 mo after inoculation autopsy was per-
formed and kidney, spleen, liver, lymph nodes, and lungs were routinely
examined for metastasis both macroscopically and microscopically . Tissue
samples fromsubcutaneous tumors and from thelungs were snap frozen and
stored at -70°C forbiochemical analysis and immunohistological staining .
Detection ofLung Metastases
At autopsy, lungs were taken for histopathological examination, fixed in for-
malin, and embedded in paraffin. To avoid missing micrometastases, 4-,um
hematoxylin- and eosin-stained sections from at least three different levels
were examined for the presence of lung metastases (59, 60) .
ImmunohistochemicalStaining ofu-PA
Indirect immunoperoxidase staining wasdone with two well-characterized
polyclonal rabbit antibodies against humanu-PA of different origins (6, 32)
on 4-Am frozen sections ofxenograft lesions of all six melanoma cell lines .
After acetone fixation, sections were processedas described by Nakane and
Pierce (40) . As the second antibody, swine-anti-rabbit IgG conjugated to
horseradish peroxidase (Dakopatts, Denmark) was used and 3-amino-9-
ethylcarbazole was used as a substrate. Harris hematoxylin (Merck, Darm-
stadt, Germany) was used to counterstain. As a control for specificity of
thehumanu-PA antibodies rabbit nonimmune serum or antibodies absorbed
with purified human u-PA were used (26) .
Results
Extracellular Matrix Degradation In Vitro
The capacity of all six melanoma cell lines to degrade ex-
tracellular matrix was tested by culturing them on 3H-
labeled extracellular matrix produced by bovine smooth
muscle cells . Five of the six cell lines hadthe capacity to de-
gradethe matrix (Fig. 1) . Only Mel 57 showed no significant
degradation of the matrix when compared to the back-
ground . In all cell lines studied, except Mel 57, matrix
degradation couldbe inhibited almost completely by aproti-
nin addition (Fig . 1), indicating the involvement of trypsin-
like proteases, probably plasmin, since there was a strong
decrease in the matrix degradation when several cell lines
were grownin theabsenceof plasminogen (serum free con-
ditionswithout addition ofplasminogen) (results notshown) .
Cultivation in the presence of specific antibodies against
t-PA showed a clear decrease in the matrix degradation
caused by the M14, IF6, and 530 cells, but had no effect on
the matrix degradation by theMV3 and BLM cells . Incuba-
tion with antibodies against u-PA showed a strong decrease
in MV3- andBLM-mediated matrix degradation, buthad no
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Figure 1 . Matrix degradation by human melanoma cell lines . The
indicatedmelanoma cell lines (105 cells) were incubated for2 d on
radiolabeled extracellular matrix produced by bovine smooth mus-
cle cells, in serum-containing medium supplemented with human
plasminogen (0.141AM), in the presence of 30 pg/ml anti-t-PA IgG
(second bar), 300 lg/ml anti-u-PA IgG (third bar), 100 U/ml
aprotinin (fourth bar), and as a control withoutany additions (first
bar) . Matrix degradation was measured by the release of radioac-
tivity into the medium . 3H released by tumor cells was expressed
as a percentage of the total 3H released by the cells and a subse-
quent treatmentofthe matrix with0.25% trypsin (1 h, 37°C) . Data
represent the average of three determinations .
effect on M14-, IF6-, and 530-mediated matrix degradation .
These results indicate that extracellular matrix degradation
is mediated by t-PA in the M14, IF6, and 530 cells and by
u-PA in MV3 and BLM cells.
Synthesis ofPA andPAI byMelanoma Cells
To determinewhich types ofplasminogen activators or plas-
minogen activator inhibitors are produced by the melanoma
cell lines tested, preparations of total RNA were analyzed
by Northern blot hybridizations, using cDNA probes for
t-PA, u-PA, PAW, and PAI-2 (Fig . 2) . In all the melanoma
cell lines studied t-PA mRNA could be detected, while in
only two cell lines, MV3 and BLM, u-PA mRNA was de-
tected . PAI-1 and PAI-2mRNA were also only detectable in
these two latter cell lines . mRNA levels andthe correspond-
Figure 2 . Northern blot analysis of RNA from different human
melanoma cell lines . RNA was isolated as described in Materials
andMethods, subjected to electrophoresis and blotted . 10 jig ofto-
tal RNA was used in each lane . The filters were subsequently hy-
bridized with cDNA fragments of human t-PA, human u-PA, hu-
manPAW and human PAI-2 . /3-actin was used as a control.
193ing protein levels were quantified in cell extracts and in con-
ditioned media in parallel cultures (Table 1) . t-PA antigen
was detected in all melanoma cell lines studied and >96
of the t-PA was found in the culture medium after 24 h incu-
bation . u-PA was only detectable in MV3 and BLM . In this
case, however, a significant fraction (16 and 30%, respec-
tively) was cell associated after 24 h incubation . PAW anti-
gen was detected in the MV3 and BLM cell lines only and
>97% was found in the culture medium . The highest levels
of PAI-2 were detected in MV3 and BLM, but also in the
other melanoma cell lines small amounts of PAI-2 were de-
tectable although no mRNA could be detected . In all cases
PAI-2 was mainly in a cell-associated form . In general, the
mRNA levels correspond well with the protein levels .
Urokinase Cross-Linking to Cell Lysates
Radiolabeled DFP-treated urokinase was incubated and cross-
linked with lysates of all six melanoma cell lines studied . In
all cell lines, a 94-kD complex was detected afterSDS-PAGE
and autoradiography. The intensity of the 94-kD band was
similar in all the cell lines except Me157, which showed con-
siderably less complex formation (Fig . 3) . In all cases com-
plex formationcould beprevented almost completely by addi-
tion of excess of unlabeled urokinase . These results indicate
that 'III-u-PA binding is saturable and that the complexes
formed have characteristics similar to u-PA/u-PAR com-
plexes formed observed with other human cell lines (41) .
Urokinase ReceptormRNA Analysis
RNA extracts of all melanoma cell lines were analyzed for
TableI. PA andPAImRNAandProtein Levels of
Melanoma CellLines In Vitro
Plasminogen activator and plasminogen activator inhibitor protein and mRNA
levels per 106 cells . mRNA levels in cells extracts were determined by dot
blots analysis . Protein levels were determined in cell extracts and in condi-
tioned medium, 25 h after media shift, using ELISA . All determinations were
performed at least in duplicate and the average numbers are given. For experi-
mental details, seeMaterials and Methods . Dashes indicate values below detec-
tion limits, i .e ., formRNA : no signal detectable on the corresponding northern
blot (Fig . 2) and for protein: 0.03 and 0.13 ng per 10 6 cells for u-PA and
PAI-1, respectively .
The Journal of Cell Biology, Volume 115, 1991
Figure 3. Lysates of human melanoma cell lines were incubated
with I'll DFP u-PA in the presence (+) or absence (-) of a 100-
fold excess ofunlabeled u-PA . As described in Materials and Meth-
ods, lysates of ti2.5 x 104 cells were used for each lane . After
crosslinking with disuccinimidyl suberate, samples were analyzed
using SDS-PAGE and visualized using autoradiography .
the presence of the u-PAR mRNA using Northern blot hy-
bridization with a specific u-PAR cDNA probe (51) . In all
the cell linesu-PARmRNA was detectable (Fig. 4), however
the intensity of the hybridization signals varied considerably.
The strongest signal was found in RNA extracts from the
MV3 and BLM cells .
TumorigenicityandMetastatic Behavior
ofMelanoma Cell Lines
To assess the tumorigenicity in nude mice, melanoma cells
were injected subcutaneously. The data concerning tumor
formation at the site ofinoculation (tumor take) are presented
Figure 4. Northern blot analysis of u-PAR mRNA for different hu-
man melanoma cell lines . 10 jig of total RNA was used per lane .
The filters were hybridized with acDNA probe for human u-PAR .
/3-actin was used as a control .
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Cell type mRNA
t-PA
Protein
% protein
in medium mRNA
u-PA
Protein
% protein
in medium
P8 ng % P8 ng %
MV3 529 34.2 98 273 418 84
M14 409 67 .7 98 - - -
IF6 368 69 .6 96 - -
BLM 348 20.9 97 75 151 70
530 1,064 128 .6 98 - - -
Me157 75 15 .0 99 - - -
PAI-1 PAI-2
% protein % protein
Cell type mRNA Protein in medium mRNA Protein in medium
P9 ng % P9 ng %
MV3 1,323 349 98 1,323 308 11
M14 - - - - 4.8 55
IF6 - - - - 25 23
BLM 622 204 97 498 99 16
530 - - - - 20 35
Mel57 - - - - 6.9 35in Table II, left. Subcutaneous tumor development varied
from 51 (M14) to 96% (MV3) of mice injected, and tumor
latency ranged from 10 d (MV3) to 40 d (530) . The capacity
to develop lung metastases after subcutaneous inoculation is
also presented in Table II, left (expressed as percentage of
mice which developed subcutaneous tumors). As canbe seen,
two of the cell lines, IF6 and 530, did not develop metastases
at all, two cell lines, M14 and Mel 57, only sporadically, and
two cell lines, MV3 and BLM, very frequently. With respect
to the nonmetastasizing cell lines IF6 and 530, we found in
an additional experiment that even 6-7 mo after subcutane-
ous tumor cell inoculation or after inoculation of 10' tumor
cells instead of the usual 1-2 x 106 cells, no lung metas-
tases couldbe observed. The difference in invasive character
ofBLM and MV3 cells compared with the less or nonmetas-
tasizing other cell lines was also consistently observed in
he subcutaneous tumors. As illustrated in Fig. 5, subcutane-
ous xenografts of IF6 were encapsulated by host stroma (Fig.
5, A and C), while MV3 (and BLM) cells were not (Fig. 5
B) . In addition, MV3 (and BLM) cells invaded into the sub-
dermal muscles (Fig. 5 D). As it appears from Table II, the
number of lesions found in the lungs of mice that developed
metastases varied strongly and both tumor cell emboli (Fig.
5 E) and invasively growing lung metastases (Fig. 5 F) were
observed.
The capacity to develop experimental metastases after in-
travenous tumor cell inoculation was investigated in another
experiment and presented in Table II, right. All melanoma
cell lines, exceptIF6, had the capacity to colonize to the lung
and form metastases with frequencies between 50 (M14) and
95% (MV3) of mice injected .
Detection ofPlasminogen Activator and Inhibitor
in Tumor Extracts
Antigen levels in extracts of subcutaneous tumors were de-
termined for t-PA, u-PA and PAW (Table IIn . Similar to the
results obtained with the corresponding cultivated cells (see
Table I), all tumors contained t-PA while u-PA and PAI-1
only were detected in those deriving from the MV3 and BLM
cell lines.
Extracts of subcutaneous tumors were also analyzed for
TableH. Tumorigenesis andMetastasis ofMelanoma Cell Lines in Nude Mice
(Left) The tumorigenicity and formation of lung metastasis after subcutaneous inoculation of various human melanoma cell lines into nude mice.
* Tumor take expressed in absolute numbers and as the percentage of the mice injected that gives tumor formation at the subcutaneous inoculation site.
f Frequency of lung lesions in absolute numbers and expressed as the percentage of the mice developing a subcutaneous tumor as detected by microscopic in-
spection of at least three lung sections from different levels.
§ Mean value of number of lesions in maximally ten randomly chosen mice with metastases or colonies counted in three lung sections from different levels.
(Right) The formation of lung colonies after intravenous inoculation.
II Frequency of lung lesions after intravenous inoculation in absolute numbers and expressed as percentage of mice inoculated, detected microscopically as
for subcutaneous inoculation.
I Mean value and range of lung lesions determined as for subcutaneous inoculation.
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the occurrence of u-PA receptor by cross-linking with 'III-
labeled DFP-treated u-PA. In all tumor extracts studied, ex-
cept in Me157, 94-kD complexes could be detected, although
at a low level (Fig. 6). After acid treatment ofthe membrane
fraction ofthe tumor extracts (a procedure which dissociates
endogenous u-PA from its receptor), a strong increase in the
complex formation in the MV3 and BLM tumor extracts
could be detected (Fig. 6) . This indicates that receptors were
present in all the tumors except Mel 57, that the levels of
u-PAR in MV3 and BLM tumors were higher than in the
tumors of the other cell lines, and that in these two tumors
most of the urokinase receptors were occupied by u-PA,
which because of a species specificity in the receptor binding
(2, 21) must be of human origin.
Immunohistochemical Localization ofu-PA in Tumors
To confirm the presence ofu-PA in the tumors caused by the
melanoma cell lines MV3 and BLM, sections of xenograft
lesions were stained immunohistologically using two differ-
ent u-PAspecific polyclonal antibodies. For both antibodies
similar results were obtained. Fig. 7, a and c shows that BLM
cellsboth in the subcutaneous tumor and in lung metastases
derived from these tumors showed a strong, evenly dis-
tributed, u-PA staining. For MV3 a similar staining pattern
was observed (data not shown). No u-PA staining was de-
tected in the xenografts of any of the other four cell lines
studied (Fig. 7 b) .
Discussion
It is found that five of the six human melanoma cell lines
tested were able to digest in vitro an extracellular matrix syn-
thesized by bovine smooth muscle cells in a largely plasmin-
dependent way. Degradation of the extracellular matrix was
markedly inhibitedby antibodies against either t-PA or u-PA.
Moreover, it was blocked nearly completely by addition of
aprotinin to the culture medium, which contained serum and
additional plasminogen. These results suggest that plasmin
is involved in the matrix degradation. As the extracellular
matrices were produced by smooth muscle cells without ad-
Subcutaneous inoculation Intravenous inoculation
Cell Number of
Tumor take* Lung metastasis# Number of
metastases Number of
Lung coloniesll Number of
colonies
line mice injected n % n % per mouse§ mice injected n % per mousel
MV3 25 24 96 22 90 9(1-25) 20 19 95 25 (3-70)
M14 45 23 51 2 9 25 (12-38) 45 22 49 50(3-150)
IF6 50 30 60 0 0 0 25 0 0 0
BLM 60 46 77 22 48 12 (3-45) 35 20 57 11 (2-30)
530 30 19 63 0 0 0 15 12 80 300 (10-800)
Me157 40 25 62 4 16 14 (3-24) 25 13 52 13 (4-30)Figure 5. Morphological aspect of subcutaneous tumors after inoculation of IF6 cells (A and C) and MV3 cells (B and D) and of the
metastases in lungs of mice subcutaneously inoculated with MV3 cells (E and F) . In the lung sections both tumor cell emboli (E) and
invasively growing metastases (F) were found . All sections were stained with haematoxylin and eosin . Bar, 1 lAm .
Table III . PA and PAI Protein Levels in Subcutaneous
Xenograft Lesions
Protein levels ofplasminogen activators and inhibitor type 1 in extracts of sub-
cutaneous tumors derived fromhuman melanoma cell lines in nude mice(dashes
indicate levels below detection limits, 0.02 and0.01 ng/mg for u-PAand PAI-1,
respectively) .
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dition of ascorbic acid to the culture medium they contain
little or no collagen (10, 29, 30) . The matrix degradation was
mediated virtually only by t-PA in three of the cell lines
(M14, IF6, and 530) while in two cell lines (BLM and MV3)
it was mediated virtually only by u-PA (Fig . 1) . Very little,
although significant matrix degradation was observed with
Mel57 cells . This matrix degradation could not be inhibited
by antibodies to u-PA or t-PA and could only partly (50%)
be inhibited by aprotinin . The finding that u-PA can mediate
degradation of extracellular matrix in this system is in agree-
ment with a previous report by Cajot et al . (10), in which
mouse L-cells transformed with the human u-PA gene were
studied.
All melanoma cell lines studied produced large quantities
of t-PAmRNA and antigen, which was mainly secreted into
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Tumors derived from
cell line t-PA u-PA PAN
ng antigen per mg wet wt
MV3 0.060 0.91 5.3
M14 0.042 - -
IF6 0.32 - -
BLM 0.072 0.28 0.56
530 0.29 - -
Mel57 0.036 - -Figure 6 . Analysis for u-PA receptor in extracts of subcutaneous
tumors derived from human melanoma cell lines (A) or isolated,
acid treated, membrane fractions (B) were incubated with 'III
DFP u-PA . After crosslinking with disuccinimidylsuberate, sam-
ples were analyzed using SDS-PAGE andvisualized using autoradi-
ography. Lysates of U937 cells were used as a positive control .
the medium (Table 1) . u-PA mRNA and protein, however,
were only detected in those cell lines, showing u-PA medi-
ated matrix degradation : BLM and MV3 . These were also
the only cell lines producing large quantities ofPAM mRNA
and protein and were also the cells with the highest PAI-2
mRNA and protein content, although PAI-2 protein was de-
tected in small amounts in all cell lines . u-PA was in theMV3
and BLM cells partly found in a cell-associated form (Table
I) . This portion of urokinase can either be located intracellu-
larly or at the cell surface, specifically bound to the uro-
kinase receptor (31, 45, 46, 55, 62) . The presence of a spe-
cific u-PA receptor in all the melanoma cell cultures was
demonstrated by cross-linking experiments with 1251 labeled
DFP-treated urokinase. Urokinase receptormRNA was also
detectable in all the melanoma cells studied . The u-PAR
mRNA analysis showed the strongest signals for MV3 and
BLM .
An interesting observation is that although all cell lines
produce t-PA, matrix degradation caused by the MV3 and
BLM cells could not be inhibited by anti-t-PA while anti-
u-PA inhibited the matrix degradation markedly. A possible
explanation might be inhibition of t-PA by PAM, in contrast
u-PA in the medium is probably unaffected byPAM because
it is mainly present in its proenzyme form (1) . Receptor-
bound u-PA can be inhibited byPAM (13) but the cell surface
pathway of u-PA catalyzed plasminogen activation may still
be efficient in the degradation ofthe extracellular matrix due
to (a) a different location of u-PA and PAM, as it has been
observed in some cell types (45) ; (b) the enhancement of
plasmin formation caused by concomitant binding or pro-
u-PA and plasminogen to cell surfaces (19, 54) ; (c) a protec-
tion of surface-bound plasmin from its serum inhibitor a z -
antiplasmin (44, 54) ; and (d) high local concentrations of
plasmin at the interphase between the cells and the matrix .
All the human melanoma cell lines could to some extent
Figure 7 Immunohistochemical staining oftumors for u-PA . Primary tumors obtained by subcutaneous inoculation of (A) BLM cells and
(B) Mel 57 cells and (C) a lung metastasis produced after subcutaneous inoculation ofBLM cells . Frozen sections were stained with
polyclonal rabbit anti-human-u-PA antibody (56) as described, with nuclear counterstaining . No staining was obtained with the antibody
after absorption with purified human u-PA (26) . Staining with a different polyclonal rabbit anti-human-u-PA antibody (32) gave identical
stain . Bar, 1 um .
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197produce subcutaneous tumors at the site of inoculation .
Since human melanoma cell lines were used in mice it was
possible to study the expression oft-PA, u-PA, and PAW by
the tumor and the metastases in vivo in the mouse tissue,
using species specific antibodies . The expression ofhuman
t-PA, u-PA, and PAI-1 in these tumors in vivo corresponded
well with the expression in vitro. t-PA was found in extracts
of all the tumors, while u-PA and PAW was found only in
theMV3 andBLM tumors . The presence ofu-PA in the MV3
and BLM tumors and its absence in the other tumors was
confirmed by the immunohistochemical studies . No mouse
u-PA could be detected in the tumors (not shown) . In extracts
of all the subcutaneous tumors, exceptthe Mel 57-derived tu-
mor, u-PAR was detectable. After mild acid treatment, u-PA
binding to lysates of the MV3 and BLM tumors increased
dramatically, indicating that in these two cases the receptor
was already largely occupied by u-PA produced by the hu-
man tumor cells, because thehuman urokinase receptor can
not efficiently bind mouse u-PA (2, 21) .
Out ofthe six cell lines only MV3 andBLM frequently de-
veloped lung metastases . These two cell lines were also the
only ones having u-PA mediated matrix degradation in vitro
and u-PA and PAI-1 production in vitro and in vivo . The
melanoma cell lines that only produce t-PA did not, or only
sporadically, develop lung metastases after subcutaneous in-
oculation . The cells forming metastasis sporadically, Me157
and M14, might use other proteolytic enzymes . Matrix
degradation experiments with Me157 reveal no inhibition by
antibodies against t-PA and u-PA and only a very limited
effect of aprotinin, suggesting the involvement of non-serine
proteases . These observations suggest a correlation between
u-PA production, PAI-1 production and frequent spontane-
ous metastasis after subcutaneous inoculation . Statistical
analysis reveals that there is only a 0.5-7% probability that
this correlation is based on chance, depending on the fact
whether u-PA andPAW production are completely indepen-
dent or strictly coupled .
All the human melanoma cell lines, except IF6, caused
lung colonies in at least 49% of the mice when inoculated
intravenously in the tail vein (Table II B) . The differences
in metastasis formation after subcutaneous versus intrave-
nous inoculation suggests that u-PA and/or PAI are involved
especially in the early steps in the metastatic cascade and not
in the lodgement ofmelanoma cells in the lung. This conclu-
sion is in contrast to previous reports in which a role ofplas-
minogen activators in formation oflung colonies after intra-
venous inoculation of tumor cells was suggested in studies
with transfection of t-PA and u-PA genes (3) or with inhibi-
tion of u-PA by preincubation with anti-catalytic u-PA anti-
bodies (27) .
Our findings suggest that the ability to metastasize after
subcutaneous inoculation is not only related to u-PA produc-
tion but possibly also to the production ofPAW and PAI-2 .
In some cell types receptor-bound pro-u-PA and u-PA is
localized to cell-cell and focal-cell substratum contact sites
(28, 45, 46, 54), and it has been proposed that a selective ac-
tivation of pro-u-PA on some of these contact sites may lead
to a directional proteolysis involved in cell migration (46,
17) . A similar role might also be played by t-PA when it oc-
curs in a surface bound form (7) . PAI-1 and PAI-2 are effec-
tive inhibitors ofu-PA evenwhen it is receptor bound (4, 13,
14, 20, 47) and it is possible that the inhibitors are required
The Journal of Cell Biology, Volume 115, 1991
for a finely tuned regulation of the surface plasminogen acti-
vation during migration of the cancer cells in the invasive
process .
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